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Abstract
Background: The pathogenesis of immunodeficiency due to human immunodeficiency virus (HIV)-1 is incompletely
understood, but immune activation is believed to play a central role. Immunomodulatory agents that decrease immune
activation may be useful in the treatment of HIV-1 infection.
Methodology: A randomized, double blind, placebo-controlled pilot study of leflunomide for 28 days was performed in
participants with HIV-1 infection who were not receiving antiretroviral therapy. Participants randomized to leflunomide
were subsequently treated with cholestyramine until leflunomide levels were below detection limit.
Findings: Treatment with leflunomide was well tolerated with mostly low-grade adverse events. Leflunomide
administration reduced cycling of CD4 T cells (by ex vivo bromodeoxyuridine uptake and Ki67 expression) and decreased
expression of activation markers (HLA-DR/CD38 co-expression) on CD8 T cells in peripheral blood. In addition, decreased
expression of HIV-1 co-receptors was observed in both CD4 and CD8 T cells in the leflunomide group. There were no
significant changes in naı ¨ve and memory T cell subsets, apoptosis of T cells or markers of microbial translocation.
Conclusions: Leflunomide was effective in reducing immune activation in the setting of chronic HIV-1 infection suggesting
that targeting immune activation with immunomodulatory agents may be a feasible strategy.
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Introduction
Infection with human immunodeficiency virus (HIV) leads to
progressive loss of CD4 T cells and clinical immunodeficiency due
to CD4 T cell lymphopenia. A number of observations suggest
that CD4 T cell depletion in HIV is not only related to direct,
virus-mediated death of infected cells but also to cell death of a
large number of uninfected bystander T cells in the setting of
increased activation that follows infection with HIV. The level of
CD8 T cell activation can predict the rate of disease progression
independent of HIV viral load [1,2]. Furthermore, the level of
immune activation prior to seroconversion has been shown to
predict faster progression to AIDS [3].
Immune activation may be seen as a normal and necessary
response toinfectiontomostpathogens.However,inHIVinfection,
chronic immune activation and increased T cell turnover play a
central role in the pathogenesis of AIDS. Both CD4 and CD8 T cell
turnover rates are increased in HIV infected individuals [4],
although HIV only infects and directly kills CD4 T cells, and CD8
T cell activation levels can predict the rate of disease progression
independent of viral load [1,2]. Simian immunodeficiency virus
(SIV)-infected sooty mangabeys, the natural host of SIV, exhibit
only minimally elevated levels of immune activation, and the
majority do not develop CD4 T cell depletion or clinical disease
despite high levels of virus replication [5]. In addition, patients
receiving anti-retroviral therapy can maintain higher than normal
levels of immune activation that may be associated with some of the
chronic non-infectious complications of HIV [4,6].
The cause of increased immune activation in HIV infection is
an area of ongoing investigation and is likely multifactorial. Host
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proteins that bind to cellular proteins [8], translocation of
microbial products across the intestinal mucosa[9], and increased
levels of pro-inflammatory cytokines [10,11,12] are among the
possible causes. Whatever the cause or causes, chronic generalized
immune activation can have several detrimental consequences. It
may serve to facilitate direct HIV infection of T cells, for example
by promoting expression of CCR5 [13]. Likewise, chemokines and
adhesion molecules are upregulated [14], leading to trafficking of
T cells to areas where HIV replication is occurring and thereby
providing more targets. Additionally, activation may lead to
fibrosis in lymph nodes and lamina propria [15,16,17], interfering
with reconstitution of those compartments. Inflammation and a
state of hypercoaguability may also lead to other non-AIDS
defining events such as myocardial infarction and stroke [18].
Taken together, these observations suggest that targeting HIV-
associated immune activation may be a promising strategy in HIV
infection. A number of immunomodulatory agents such as
hydroxyurea [19,20], mycophenolate mofetil [21,22], and cyclo-
sporine [23] have been studied with mixed results, with certain
toxicities, risk of infection and lack of clear clinical efficacy
preventing their use in clinical practice. Leflunomide is an
immunomodulatory agent that is approved for the treatment of
rheumatoid arthritis. The primary metabolite of leflunomide
reversibly inhibits dihydroorotate dehydrogenase, the rate limiting
step in the de novo synthesis of pyrimidines [24]. Unlike other
cells, activated lymphocytes expand their pyrimidine pool by eight
to sixteen-fold during proliferation and must use both salvage and
de novo pathways of synthesis to meet this demand. In the
presence of leflunomide, there is inhibition of T cell proliferation
[25,26]. By decreasing the supply of pyrimidines, leflunomide
leads to interruption of cell cycle and decreased proliferation of
activated lymphocytes and therefore is an interesting potential
therapeutic agent in the treatment of HIV-1 infection.
Leflunomide has been studied in the treatment of other viral
infections such as CMV and BK virus infections with promising results
[27,28]. In vitro studies have demonstrated an inhibitory effect of
leflunomide on HIV replication in PBMCs alone and in combination
with antiretroviral agents [29,30], but to date there have been no
reports of leflunomide treatment of HIV infected participants,
whether directed at rheumatoid arthritis or viral infection.
In this study, we performed a randomized, double-blinded,
placebo-controlled pilot study of leflunomide administered to HIV
infected participants who were not on antiretroviral therapy in
order to assess its safety and tolerability in this population as well
as its effect on cycling and activation of CD4 and CD8 T cells.
Methods
Participants
HIV-1 infected persons $18 years of age were recruited from
the NIAID outpatient HIV clinic. They were eligible to participate
if they were not taking antiretroviral therapy (ART), had a CD4 T
cell count $350 cells/mm
3, a plasma HIV–RNA level
$1000 copies/mL at the time of screening and a historical nadir
CD4 T cell count of $200 cells/mm
3. Routine laboratory results
had to be within acceptable ranges. Specific exclusionary
laboratory values were hemoglobin ,10 g/dL, absolute neutro-
phil count ,1000/mm
3, platelets ,100,000/mm
3, and alanine
aminotransferase, aspartate aminotransferase, or alkaline phos-
phatase .1.25 times the upper limit of normal. Because
leflunomide can have significant hepatotoxicity participants were
not receiving ART and were also excluded if they had liver
disease, including chronic viral hepatitis, or were taking concom-
itant immunomodulatory agents or medications that could interact
with leflunomide or cholestyramine. Pregnant or breast-feeding
women were excluded, as were participants with a history of AIDS
defining illness, neoplasm or acute bacterial infection. All
participants provided written, informed consent. The protocol
was approved by the NIAID Institutional Review Board, was
monitored by a data safety monitoring board and was conducted
under a United States FDA investigational new drug application
(NCT00101374). The protocol, consent and IRB approval for this
trial and supporting CONSORT checklist are available as
supporting information; see Protocol S1, Consent S1, IRB
Approval S1 and Checklist S1.
Study design
The primary objective was evaluation of safety and secondary
objectives included evaluation of biologic activity as measured by
cycling and activation of T cells as well as expression of chemokine
receptors. At entry, eligible participants were assigned by the
central telephone (located in Pharmacy Department) using
permuted block randomization in a 2:1 ratio to receive
leflunomide (AravaH, Sanofi Aventis) 20 mg orally (standard dose
for RA) or matching placebo daily for 28 days. Loading with
100 mg orally for three days was not done to avoid acute side
effects that could lead to unblinding and early withdrawal. The
allocation sequence was concealed from all study staff. Participants
and all study team members were blinded to treatment assignment
during the 28-day treatment period. Treatment assignment was
unblinded to the participant and clinic staff at the end of 28 days.
Staff performing laboratory assays remained blinded until the
completion of all assays. Because of the long half-life of
leflunomide (2 weeks), those who were assigned to leflunomide
underwent a washout procedure during which they were
administered open-label cholestyramine (decreases leflunomide
levels) for 11 days or longer until M1 (main leflunomide
metabolite) levels were below the limit of detection to avoid
potential synergistic hepatotoxicity if ART was started within the
following weeks to months. The study safety and endpoint data
were reviewed annually by an independent data and safety
monitoring board. Participants were seen on days 1 (first day of
study drug), 15 and 29 (end of study drug and unblinding) for
clinical evaluation and study procedures. Leflunomide recipients
were also seen on day 43 (after the wash out) and as needed if the
first wash out was unsuccessful.
Study evaluations
HIV-RNA levels were determined by ultrasensitive bDNA
assay (Versant HIV-1 version 3.0, Siemens Corp., New York
City). Leflunomide metabolite (A77 1726 or M1) levels were
measured in plasma by Labcorp Clinical Trials Department
(Burlington, NC) using high performance liquid chromatogra-
phy. Immunophenotypic analysis was performed on days 1, 15
a n d2 9o nw h o l eb l o o db yu s eo f4 - c o l o ri m m u n o f l u o r e s c e n c ea s
described elsewhere [31]. The following monoclonal antibodies
were used for staining: CD3, CD4, CD8, CD27, CD45RO,
CD38, HLA-DR, CCR5, and CXCR4 conjugated to fluores-
cein isothiocyanate, phycoerythrin, peridinin-chlorophyll-pro-
tein or allophycocyanin (Becton Dickinson (BD) Pharmingen,
San Jose, CA). To study naive and memory phenotypes, subsets
were defined by surface staining with CD3, CD4, CD45RO,
and CD27 antibodies. Naive cells were defined as
CD45RO
2CD27
+, central memory as CD45RO
+CD27
+,
effector memory as CD45RO
+CD27
2, and effectors as
CD45RO
2CD27
2. Annexin V and 7AAD staining was
performed to assess for apoptosis as previously described [31].
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hypothesized that a decrease in effector or effector memory T
cells could be seen. Staining for the nuclear antigen Ki67 was
performed using Ki67 phycoerythrin (BD Immunocytometry
Systems, San Jose, CA) following the protocol recommended by
the manufacturer. Ex vivo bromodeoxyuridine (BrdU) staining
was performed as previously described [32]. Plasma samples
from days 1 and 29 were analyzed by ELFA (Enzyme Linked
Fluorescent Assay) on a VIDAS instrument for D-Dimer
(bioMerieux Inc., Durham, NC), by a single-plex kit (Meso
Scale Discovery, Gaithersburg, MD) for C-reactive protein
(CRP) and by real time PCR for Cytomegalovirus (CMV) DNA
quantification as described by Yun et al [33]. Plasma levels of
lipopolysaccharide (LPS) were also measured by the limulus
assay as previously described [9] and soluble CD14 by
commercially available ELISA assays (R&D Systems, Minnea-
polis, MN).
Samples were collected on an Epics XL (Beckman Coulter,
Fullerton, CA), a FACSCanto (BD Immunocytometry Systems), or
a FACSCalibur (BD Immunocytometry Systems) flow cytometer
using CellQuest software (BD, San Jose, CA). Flow cytometry data
were analyzed using FlowJo software (version 7.2.5, TreeStar
Incorporated, Ashland, OR).
Sample Size Considerations
The study was designed to compare the change from baseline to
day 29 in the percentage of CD4 T cells expressing Ki67 between
the two treatment groups with a 2:1 randomization favoring
leflunomide. For sample size calculation using previous data [4],
the estimate of mean Ki67 expression was assumed to be 4.0% and
the standard deviation of change to be 0.60. A sample size of
fifteen would allow detection of a 30% drop in the mean Ki67
expression with 90% power using a two-sided t-test with type 1
error rate set to 0.05. To allow for 17% dropout, 18 participants
were recruited.
Statistical Analysis
Nonparametric tests were used for all analyses and median
values are reported throughout. Changes from baseline within
each group at 15 and 29 days were evaluated using the Sign test.
Data comparisons between the two groups were performed using
the Wilcoxon rank-sum test. Analyses were performed per
protocol. Given the exploratory nature of this study, there was
no adjustment for multiple testing.
Results
Participant characteristics
Forty-one potential participants were screened for the study
between April 2005 and April 2007. Twenty-three participants
were found ineligible. The majority had an exclusionary
laboratory value, including eight participants with a CD4 T
cell count less than 350 cells/mm
3 and five participants with
an HIV-RNA less than 1000 copies/mL. Eighteen participants
were enrolled onto the study; 12 were assigned to leflunomide,
and 6 were assigned to placebo (Figure 1). The two groups
were well matched with no statistically significant differences
in baseline characteristics (Table 1). Two participants ran-
domized to the leflunomide arm discontinued treatment early.
One participant developed oral ulcers on Day 2 that were
judged to be probably unrelated to study treatment, and one
participant chose to come off study early. Therefore there were
10 participants in the leflunomide group for per protocol
analyses.
Toxicity data
Two serious adverse events were reported during this study.
One participant assigned to leflunomide experienced grade 3
neutropenia on Day 43. Because this participant had a history of
neutropenia, had grade 2 neutropenia on a pre-entry visit, and
developed this adverse event at a time when the leflunomide level
was undetectable, this event was judged to be unrelated to
treatment. A second participant, who was also assigned to
leflunomide, was hospitalized on Day 54 for grade 3 depression
and suicidal ideation. This participant had a history of depression
and one previous suicidal gesture. The event was judged to be
unrelated to treatment. There were no grade 4 signs, symptoms or
laboratory abnormalities reported during this study.
Four participants in the leflunomide group reported three grade
2 events (headache, elevated lipase, and neutropenia) and nine
grade 1 events (headache, fatigue, rash, dry mouth, taste
Figure 1. Flow chart of clinical study.
doi:10.1371/journal.pone.0011937.g001
Table 1. Participant baseline characteristics
A (median value
with interquartile range in parentheses).
Leflunomide Placebo
(N=10) (N=6)
Gender (%male) 90% 67%
Age (yrs) 40 39
(26–44) (30–43)
HIV-1 RNA (log10) 3.87 4.31
(3.69–4.09) (3.60–4.75)
%CD4 32 32
(20–35) (30–35)
CD4 T cells/mL 434 637
(337–503) (597–676)
%CD8 49 55
(38–56) (47–61)
CD8 T cells/mL 814 961
(520–1063) (932–1175)
4:8 Ratio 0.70 0.58
(0.37–0.92) (0.46–0.70)
AThere were no statistically significant differences in baseline characteristics
between groups.
doi:10.1371/journal.pone.0011937.t001
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lipase and hyperbilirubinemia) that were at least possibly related to
leflunomide or placebo. Three of the six participants in the
placebo group reported five grade 1 events (diarrhea, nausea,
increased ALT, increased AST, and hyperbilirubinemia). In
addition, two participants in the leflunomide group reported
inability to comply with the cholestyramine washout as prescribed
due to unpleasant taste and consistency and frequency of dosing.
Leflunomide metabolite (A77 1726 or M1) levels
The Day 29 plasma M1 level achieved in this treatment group
was 21.50 mg/L (range 12.3–41.0 mg/L). All participants in the
leflunomide group were able to achieve levels below the limit of
detection (,0.02 mg/L) following administration of cholestyr-
amine, with the exception of two participants who were lost to
follow up before a level of ,0.02 mg/L could be documented.
Five of the ten participants who completed 29 days of leflunomide
required two courses of cholestyramine to achieve a level
,0.02 mg/L.
Changes in T cell counts and plasma HIV-RNA
There were no statistically significant changes in CD4
(Figure 2A) or CD8 (Figure 2B) T cell counts during the study.
A statistically significant decrease in plasma HIV-RNA was seen in
the leflunomide group at Day 15 (median change, 20.1 log10
copies/mL; p-value=0.02), however the change from baseline in
this group was not significant at Day 29 and was comparable to
the change in the placebo group (Figure 2C).
Changes in lymphocyte cycling and phenotype
Expression of Ki67, a nuclear antigen expressed by cells in cell
cycle, was also comparable between the two groups at baseline
(leflunomide 4.3% vs placebo 5.6%, p-value=0.79) (Table 2).
Ki67 expression decreased significantly in the leflunomide group
from baseline to Day 29 (median change, 20.8%; p-value=0.02)
(Figure 3A) and remained stable in the placebo group (median
change, 20.05%; p-value=1.0). However, the comparison of
changes in Ki67 expression in CD4 T cells between the two
treatment groups did not reach statistical significance (p-
value=0.55).
Ex-vivo BrdU incorporation, another marker of cell cycling (in
S phase), was also examined. Baseline values for CD4 T cells did
not differ between groups (Table 2). BrdU incorporation in the
CD4 T cells in the leflunomide group decreased significantly at
Day 15 and Day 29 from baseline (change at Day 15, 20.14% and
at Day 29, 20.08%). This decrease was significantly different
(p=0.03) from the changes seen in the placebo group (at Day 15,
0.05% and at Day 29, 0.09%) (Figure 3B).
There were no differences between groups in frequency of
activated CD8 T cells, co-expressing markers of activation CD38
and HLA-DR, at baseline (Table 2). A decrease in frequency of
activated CD8 T cells was observed in the leflunomide group at
Day 29 (median change, 25%; p-value=0.02) (Figure 3C) but not
in the placebo group. Activated CD4 T cells (HLA-DR+CD38+)
did not decrease in either group (Figure 3D).
Expression of the HIV-1 co-receptors CCR5 and CXCR4 by
CD4 and CD8 T cells did not differ significantly at baseline
(Table 2). In the leflunomide group, there were significant
decreases in frequency of both CD4 (Figure 4A) and CD8
(Figure 4B) T cells expressing CCR5 at Day 15 (CD4: 22.8%, p-
value=0.02; CD8: 22.2%, p-value=0.02) and Day 29 (CD4:
23.9%, p-value=0.02; CD8: 28.5%, p-value=0.02) as com-
pared to baseline, whereas no significant changes were seen in the
placebo group at Day 15 or Day 29. Decreases in expression of
CXCR4 were also seen in both CD4 (Figure 4C) and CD8
(Figure 4D) T cells in the leflunomide group at Day 15 (CD4:
26.8%, p-value=0.02; CD8: 210.4%, p-value=0.02) and Day
29 (CD4: 23.6%, p-value=0.02; CD8: 29.6%, p-value=0.002)
but not in the placebo group at either time point.
Figure 2. Changes in T cell counts and HIV viral load. A) Changes
from baseline in CD4 T cell counts, and B) CD8 T cell counts throughout
the study duration; median values and interquartile ranges; C) Change
from baseline in HIV plasma viral load; median values and interquartile
ranges. There was a significant decrease in HIV-1 RNA at Day 15 in the
leflunomide group (*p-value,0.05).
doi:10.1371/journal.pone.0011937.g002
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effector memory, or effector phenotype did not change signifi-
cantly in either group (data not shown). There were also no
changes seen in either group in frequency of apoptotic cells as
measured by Annexin V or 7AAD staining, plasma LPS, soluble
CD14, D-dimer and CRP levels (data not shown). Plasma CMV
PCR was positive in a very small number of participants (N=6) at
barely detectable levels to allow any meaningful comparisons.
Discussion
In this study, short-term administration of leflunomide to HIV-1
infected participants not receiving antiretroviral therapy was
overall well tolerated and led to decreases in CD4 T cell cycling
and CD8 T cell activation as well as decreases in expression of
both CCR5 and CXCR4 without any significant effects on T cell
counts or plasma HIV-1 levels.
Despite the short exposure and the overall low plasma levels of
leflunomide a decrease in cycling of CD4 T cells was observed in
the treatment group. A decrease in both BrdU incorporation by
CD4 T cells and CD38/HLA-DR expression on CD8 T cells was
Figure 3. Changes in markers of CD4 T cell cycling and CD8 T cell activation. A) Change from baseline in percent Ki67 expression in CD4 T
cells; median values and interquartile ranges. There was a significant decrease in Ki67 expression by CD4 T cells at Day 29 in the leflunomide group
(*p-value,0.05). B) Change from baseline in percent BrdU incorporation by CD4 T cells; median values and interquartile ranges. There was a
significantly greater change in BrdU incorporation by CD4 T cells in the leflunomide group compared to the placebo group at Day 15 and Day 29
(**p-value,0.05). C) Change from baseline in percent of activated CD8 T cells (%CD8CD38+HLADR+), median values and interquartile ranges. There
was a significant decrease in activated CD8 T cells at Day 29 in the leflunomide group (*p-value,0.05). D) Change from baseline in percent of CD4 T
cells co-expressing CD38 and HLA-DR, median values and interquartile ranges.
doi:10.1371/journal.pone.0011937.g003
Table 2. Participant baseline levels of turnover, activation
and coreceptor expression
A (median value with interquartile
range in parentheses).
Leflunomide Placebo
%CD4+Ki67+ 4.3 (3.9–7.2) 5.6 (4.1–7.0)
%CD4+BrdU+ 0.37 (0.22–0.43) 0.26 (0.12–0.55)
%CD4+CD38+DR+ 9 (6–13) 11 (8–26)
%CD4+CCR5+ 14 (9–19) 16 (9–22)
%CD4+CXCR4+ 90 (88–91) 77 (63–89)
%CD8+Ki67+ 3.0 (2.3–3.6) 4.7 (1.4–7.3)
%CD8+BrdU+ 0.18 (0.13–0.25) 0.31 (0.09–0.54)
%CD8+CD38+DR+ 39 (35–53) 46 (31–62)
%CD8+CCR5+ 41 (32–51) 40 (29–61)
%CD8+CXCR4+ 74 (62–83) 60 (40–65)
AThere were no statistically significant differences in baseline immunologic
variables between groups.
doi:10.1371/journal.pone.0011937.t002
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indicating a decrease in T cell cycling and activation. Rates of
apoptosis were not affected, nor were markers of microbial
translocation (LPS, sCD14) or inflammation (CRP), supporting the
role of leflunomide in inhibiting cycling of activated lymphocytes
as the main mechanism behind the decrease in activation levels.
Similar to results from in vitro studies published previously [30],
expression of HIV-1 co-receptors CCR5 and CXCR4 also
decreased following leflunomide treatment. A decrease in CCR5
expression on CD4 T lymphocytes may be a desirable outcome in
better controlling chronic HIV-associated activation as suggested
by the non-pathogenic SIV primate models [34].
The overall low levels achieved at Day 29 (21.5 mg/L)
compared to the steady-state levels expected in treatment of
rheumatoid arthritis (50–100 mg/L) may have blunted T cell
effects. Studies of the treatment of both rheumatoid arthritis and
BK virus infection have demonstrated a concentration-effect
relationship with leflunomide [35,36]. Although there is marked
inter-individual variability in the pharmacokinetics of leflunomide,
it is likely that a longer course of therapy in this study could have
resulted in higher levels and potentially a more dramatic effect on
T cell activation. Unfortunately, clinical use of leflunomide is not
without risks and the prolonged half-life makes its use very
complicated. There is potential for hepatotoxicity and pancytope-
nia as well as potential teratogenicity, making it an unattractive
drug to combine with ART. In this study though, in a very
rigorously selected group of HIV+ participants, a short course was
safe and well-tolerated in the absence of ART, but we doubt its
potential for broader use and applicability.
In conclusion, leflunomide was well tolerated and effective in
decreasing T cell turnover in HIV-infected participants but
potential toxicities and long half-life would limit further study as
possible adjunct immune therapy in HIV. However newer drugs
with similar mechanisms of action could potentially be further
pursued as an experimental treatment to decrease immune
activation in HIV infection either as adjunct therapy to ART to
decrease immune activation in treated patients or potentially to
defer ART initiation.
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